Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmaxis Ltd.
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.
The first of six new compounds are expected to begin Phase II testing soon as part of the UK’s ACCORD initiative, a randomized platform trial bringing together government, industry and research organisations to find potential treatments for COVID-19.
A Milbank Quarterly study and a Pink Sheet analysis show that disagreement between the US FDA and its advisory committee meetings doesn't happen often; it is even rarer for the agency to approve a drug against the advice from a panel.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Topigen Pharmaceuticals, Inc.